Phenotyping of Human CYP450 Enzymes by Endobiotics: Current Knowledge and Methodological Approaches
- 27 May 2019
- journal article
- review article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 58 (11) , 1373-1391
Abstract
Drug response is subject to an important within- and between-individual variability owing, mainly, to pharmacokinetic and pharmacodynamic factors. Pharmacokinetics includes metabolism by cytochrome P450 (CYP450), major enzymes of phase I reactions that are responsible for the biotransformation of around 60% of the currently approved drugs. CYP450 activity and/or expression are influenced by multiple intrinsic and extrinsic factors, such as drug–drug interactions or genetic polymorphisms. Present phenotyping strategies with xenobiotics used to assess CYP450 activity could be replaced by less invasive procedures using endogenous CYP450 biomarkers. In this work, we review existing knowledge on endobiotics and their ability to characterise variability of the CYP1A2, CYP2C19, CYP2D6 and CYP3A enzymes in humans. To date, it appears that there is a lack of clinical data for the majority of the endogenous compounds described in the literature or some important limitations to allow their use in clinical practice. Additional studies are needed to fill the gap or to identify new candidates, in particular through the use of metabolomics. The use of multivariate models is also a very promising approach to enhance prediction by combining several endogenous phenotyping metrics and other covariates.Keywords
This publication has 115 references indexed in Scilit:
- Applications of CYP450 Testing in the Clinical SettingMolecular Diagnosis & Therapy, 2013
- An Inducible Cytochrome P450 3A4-Dependent Vitamin D Catabolic PathwayMolecular Pharmacology, 2012
- Evaluation of 6β-Hydroxycortisol, 6β-Hydroxycortisone, and a Combination of the Two as Endogenous Probes for Inhibition of CYP3A4 In VivoClinical Pharmacology & Therapeutics, 2011
- A Phenotype–Genotype Approach to Predicting CYP450 and P-Glycoprotein Drug Interactions With the Mixed Inhibitor/Inducer Tipranavir/RitonavirClinical Pharmacology & Therapeutics, 2010
- Cytochrome P450-mediated metabolism in the human gut wallJournal of Pharmacy and Pharmacology, 2009
- Pinoline May be Used as a Probe for CYP2D6 ActivityDrug Metabolism and Disposition, 2009
- 4β‐Hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half‐life of elimination after induction with rifampicinBritish Journal of Clinical Pharmacology, 2008
- Poor correlation between 6β‐hydroxycortisol:cortisol molar ratios and midazolam clearance as measure of hepatic CYP3A activityBritish Journal of Clinical Pharmacology, 2006
- MPTP, the neurotoxin inducing parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufI, P450db1) catalyzing debrisoquine 4-hydroxylationBiochemical and Biophysical Research Communications, 1987
- Morphine and codeine are endogenous components of human cerebrospinal fluidLife Sciences, 1987